Alterity Therapeutics (ATHE) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.72, -3.20% vs the prior close of $2.81.
- Volume 37.50K shares, 1.9x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ATHE slides 3.2% to $2.72, a 52-week low on 1.9x normal volume. Closed at $2.72, -3.20% vs the prior close of $2.81. Day range $2.62–$2.84, opened at $2.67.
ATHE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ATHE slides 3.2% to $2.72, a 52-week low on 1.9x normal volume
- Closed at $2.72, -3.20% vs the prior close of $2.81. Day range $2.62–$2.84, opened at $2.67.
- Volume was 37.50K shares, 1.9x its 50-day average of 19.73K — unusually heavy trading.
- Price is -32.3% vs its 50-day average ($4.02) and -32.6% vs its 200-day average ($4.04).
- 52-week range $2.62–$5.89; today's close sits at 3% of that range, 53.8% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — ATHE dips 1.4% to $2.81, a 52-week low on 2.8x normal volume
- Closed at $2.81, -1.40% vs the prior close of $2.85. Day range $2.78–$3.40, opened at $2.88.
- Volume was 53.20K shares, 2.8x its 50-day average of 18.71K — unusually heavy trading.
- Price is -30.7% vs its 50-day average ($4.05) and -30.4% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 5% of that range, 52.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ATHE dips 2.7% to $2.85, a 52-week low
- Closed at $2.85, -2.73% vs the prior close of $2.93. Day range $2.80–$2.95, opened at $2.94.
- Volume was 19.00K shares, 1.0x its 50-day average of 18.40K.
- Price is -30.2% vs its 50-day average ($4.08) and -29.4% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 6% of that range, 51.6% below the 52-week high.
Oct 12, 2026 — ATHE slides 6.1% to $2.93, a 6-month low
- Closed at $2.93, -6.09% vs the prior close of $3.12. Day range $2.82–$3.09, opened at $3.07.
- Volume was 31.50K shares, 1.8x its 50-day average of 17.85K.
- Price is -28.8% vs its 50-day average ($4.12) and -27.5% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 8% of that range, 50.3% below the 52-week high.
Oct 9, 2026 — ATHE rises 1.6% to $3.12
- Closed at $3.12, +1.63% vs the prior close of $3.07. Day range $3.07–$3.25, opened at $3.07.
- Volume was 22.70K shares, 1.3x its 50-day average of 17.58K.
- Price is -24.7% vs its 50-day average ($4.15) and -22.8% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 14% of that range, 47.0% below the 52-week high.
- SEC filings that day: 6-K.
Oct 8, 2026 — ATHE slides 7.5% to $3.07, a 6-month low on 2.0x normal volume
- Closed at $3.07, -7.53% vs the prior close of $3.32. Day range $3.04–$3.34, opened at $3.21.
- Volume was 34.40K shares, 2.0x its 50-day average of 16.94K — unusually heavy trading.
- Price is -26.4% vs its 50-day average ($4.17) and -24.0% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 13% of that range, 47.9% below the 52-week high.
Oct 7, 2026 — ATHE dips 1.5% to $3.32
- Closed at $3.32, -1.48% vs the prior close of $3.37. Day range $3.29–$3.51, opened at $3.41.
- Volume was 19.30K shares, 1.2x its 50-day average of 16.60K.
- Price is -21.0% vs its 50-day average ($4.20) and -17.9% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 20% of that range, 43.6% below the 52-week high.
Oct 6, 2026 — ATHE jumps 4.7% to $3.37
- Closed at $3.37, +4.66% vs the prior close of $3.22. Day range $3.22–$3.46, opened at $3.34.
- Volume was 21.90K shares, 1.3x its 50-day average of 16.24K.
- Price is -20.3% vs its 50-day average ($4.23) and -16.6% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 22% of that range, 42.8% below the 52-week high.
Oct 5, 2026 — ATHE slides 6.7% to $3.22, a 6-month low on 3.5x normal volume
- Closed at $3.22, -6.67% vs the prior close of $3.45. Day range $3.10–$3.29, opened at $3.29.
- Volume was 54.60K shares, 3.5x its 50-day average of 15.50K — unusually heavy trading.
- Price is -24.3% vs its 50-day average ($4.25) and -20.3% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 17% of that range, 45.3% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 6-K.
Oct 2, 2026 — ATHE dips 1.1% to $3.45, a 6-month low on 3.2x normal volume
- Closed at $3.45, -1.15% vs the prior close of $3.49. Day range $3.25–$3.46, opened at $3.39.
- Volume was 47.20K shares, 3.2x its 50-day average of 14.75K — unusually heavy trading.
- Price is -19.4% vs its 50-day average ($4.28) and -14.5% vs its 200-day average ($4.04).
- 52-week range $2.66–$5.89; today's close sits at 24% of that range, 41.4% below the 52-week high.
- That makes 3 straight losses.
ATHE latest news & SEC filings
Every SEC filing by or about ATHE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 5, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 25, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 23, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 18, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 16, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Marks Peter Ashley bought 47,620 shares at $0.50 (≈$23.81K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 3, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 1, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade ATHE
- How much it moves: over the last 20 sessions the average daily move was 3.65% (largest 7.5%). That is a volatile stock.
- Liquidity: about 23.84K shares (≈$64.83K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.72 vs a range of $2.62–$5.89 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 0 sales; latest: Peter Ashley Marks bought 47,620 shares on Aug 31, 2026.
- Latest filings: 6-K Oct 9, 2026; 6-K Oct 5, 2026; 6-K Sep 25, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ATHE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.67 | 2.84 | 2.62 | 2.72 | 37.50K |
| Oct 14, 2026 | 2.88 | 3.40 | 2.78 | 2.81 | 53.20K |
| Oct 13, 2026 | 2.94 | 2.95 | 2.80 | 2.85 | 19.00K |
| Oct 12, 2026 | 3.07 | 3.09 | 2.82 | 2.93 | 31.50K |
| Oct 9, 2026 | 3.07 | 3.25 | 3.07 | 3.12 | 22.70K |
| Oct 8, 2026 | 3.21 | 3.34 | 3.04 | 3.07 | 34.40K |
| Oct 7, 2026 | 3.41 | 3.51 | 3.29 | 3.32 | 19.30K |
| Oct 6, 2026 | 3.34 | 3.46 | 3.22 | 3.37 | 21.90K |
| Oct 5, 2026 | 3.29 | 3.29 | 3.10 | 3.22 | 54.60K |
| Oct 2, 2026 | 3.39 | 3.46 | 3.25 | 3.45 | 47.20K |
| Oct 1, 2026 | 3.53 | 3.57 | 3.38 | 3.49 | 23.20K |
| Sep 30, 2026 | 3.47 | 3.87 | 3.46 | 3.65 | 30.30K |
| Sep 29, 2026 | 3.50 | 3.89 | 3.41 | 3.66 | 21.40K |
| Sep 28, 2026 | 3.60 | 3.60 | 3.50 | 3.50 | 10.40K |
| Sep 25, 2026 | 3.72 | 3.72 | 3.60 | 3.67 | 2.50K |
| Sep 24, 2026 | 3.61 | 3.99 | 3.61 | 3.77 | 5.60K |
| Sep 23, 2026 | 3.83 | 3.98 | 3.50 | 3.55 | 15.70K |
| Sep 22, 2026 | 3.78 | 4.00 | 3.75 | 3.78 | 11.80K |
| Sep 21, 2026 | 3.88 | 3.90 | 3.65 | 3.78 | 11.40K |
| Sep 18, 2026 | 3.85 | 3.92 | 3.80 | 3.91 | 3.10K |
About Alterity Therapeutics
Alterity Therapeutics (ATHE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MELBOURNE. State of incorporation: Australia. Fiscal year ends June 30. SEC CIK 1131343.
ATHE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Julian Michael Babarczy | Director | Jun 23, 2026 |
| Ann Michelle Cunningham | Director | Apr 29, 2026 |
| Lawrence Bernard Gozlan | Director | Jun 23, 2026 |
| Peter Ashley Marks | Director | Sep 8, 2026 |
| David Allen Stamler | Chief Executive Officer | Sep 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Niven Abby Sarah Macnish | Chief Financial Officer | Apr 9, 2026 |
| David Allen Stamler | Chief Executive Officer | Sep 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 31, 2026 | Peter Ashley Marks | Buy | 47,620 | $0.50 |
ATHE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
ATHE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ATHE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.